DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant

Phase 1

Completed

Conditions: Hematologic Malignancy

First Posted Date: 2007-05-21

Last Posted Date: 2012-03-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00476177

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

ALL Adult Consortium Trial: Adult ALL Trial

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Doxorubicin
Drug: Cytarabine
Drug: Methotrexate
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Methylprednisone
Drug: Hydrocortisone Sodium Succinate
Drug: Dexamethasone
Drug: 6-MP
Drug: PEG-Asparaginase
Drug: Imatinib
Drug: Etoposide
Procedure: Radiation Therapy
Drug: E. coli Asparaginase

First Posted Date: 2007-05-21

Last Posted Date: 2025-03-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 112

Registration Number: NCT00476190

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of Boston, Boston, Massachusetts, United States

and more 12 locations

Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery

Not Applicable

Terminated

Conditions: Prostate Cancer

Interventions: Dietary Supplement: omega-3 fatty acids
Procedure: biopsy

First Posted Date: 2007-04-11

Last Posted Date: 2018-07-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 232

Registration Number: NCT00458549

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Phase 1

Completed

Conditions: Metastatic, Androgen Independent Prostate Cancer
Prostate Cancer

Interventions: Drug: RAD001
Drug: Docetaxel
Drug: Prednisone

First Posted Date: 2007-04-11

Last Posted Date: 2016-05-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00459186

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 2 locations

Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Docetaxel
Drug: ZD6474

First Posted Date: 2007-04-11

Last Posted Date: 2013-07-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00459043

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Loyola University Medical Center/Cardinal Bernadin Cancer Center, Maywood, Illinois, United States

Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: GM-K562 vaccine
Procedure: stem cell transplantation

First Posted Date: 2007-03-01

Last Posted Date: 2020-09-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT00442130

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2007-02-16

Last Posted Date: 2012-10-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT00436072

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Phase 1

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Biological: Epstein-Barr virus-specific adoptive T-cells immunotherapy

First Posted Date: 2007-02-05

Last Posted Date: 2017-04-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 28

Registration Number: NCT00431210

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Natural History Study of Patients With Chronic Myelogenous Leukemia

Completed

Conditions: Leukemia

First Posted Date: 2007-02-01

Last Posted Date: 2017-01-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 48

Registration Number: NCT00429910

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Procedure: Leukemia cell harvest

First Posted Date: 2007-01-29

Last Posted Date: 2020-04-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 65

Registration Number: NCT00428233

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy